drug

ABI-6250

3 stories · latest Aug 14, 2026

Timeline

Assembly Bio files 8-K/A to correct filing tag on Q2 2026 results release

Aug 14Quarterly updateABI-6250 Assembly Biosciences

Assembly Bio reports Q2 2026 results, expands ABI-6250 into cholestatic liver disease

Aug 13M&AABI-6250 Assembly Biosciences

Assembly Biosciences registers Phase 2 trial of ABI-6250 for chronic hepatitis D

Aug 13Trial updateABI-6250 Assembly Biosciences